查看文章

To identify serum protein biomarkers that might distinguish patients with early inflammatory arthritis (IA) with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA) and may be used to support appropriate early intervention.

The serum proteome of patients with PsA and patients with RA was interrogated using nano–liquid chromatography mass spectrometry (nano‐LC‐MS/MS) (n = 64 patients), an aptamer‐based assay (SomaScan) targeting 1,129 proteins (n = 36 patients), and a multiplexed antibody assay (Luminex) for 48 proteins (n = 64 patients). Multiple reaction monitoring (MRM) assays were developed to evaluate the performance of putative markers using the discovery cohort (n = 60 patients) and subsequently an independent cohort of PsA and RA patients (n = 167).

Multivariate machine learning analysis of the protein discovery data from the 3 platforms revealed that …